VivoSeq
Infectious Disease

Antibiotic-Resistant Bacteria

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Antibiotic-resistant Bacteria is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Unknown status2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy
Unknown status·—·Phase 2·NCT02472600·39 enrolled
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
Unknown status·MMEDSI Clinical Hospital 1, ICU·N/A·NCT04839653·60 enrolled
Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients
Recruiting·EEmory University·Phase 2·NCT05835206·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)